Stockscreener 앱 받기
2.86
2.05%
-0.06
시간 외 거래:
2.86
전일 마감가:
$2.92
열려 있는:
$2.91
하루 거래량:
609.44K
Relative Volume:
0.47
시가총액:
$238.55M
수익:
$13.86M
순이익/손실:
$-81.74M
주가수익비율:
-2.1939
EPS:
-1.3036
순현금흐름:
$-66.98M
1주 성능:
-14.11%
1개월 성능:
-6.54%
6개월 성능:
+100.00%
1년 성능:
+38.83%
1일 변동 폭
$2.785
$2.92
1주일 범위
$2.785
$3.405
52주 변동 폭
$1.03
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
명칭
Pyxis Oncology Inc
전화
(617) 221-9059
주소
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
2.86 | 238.55M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-11-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-08-08 | 개시 | Stifel | Buy |
| 2024-05-07 | 재개 | Jefferies | Buy |
| 2024-02-09 | 개시 | BTIG Research | Buy |
| 2024-01-23 | 개시 | Leerink Partners | Outperform |
| 2023-09-05 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-02 | 개시 | BofA Securities | Neutral |
| 2021-11-02 | 개시 | Credit Suisse | Outperform |
| 2021-11-02 | 개시 | Jefferies | Buy |
모두보기
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pyxis Oncology stock falls 3.73 percent after trial update - AD HOC NEWS
Pyxis Oncology Inc (PYXS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Pyxis Oncology, Inc.(NasdaqGS: PYXS) added to S&P Global BMI Index - marketscreener.com
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - kalkine.com.au
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery (NASDAQ:PYXS) - Seeking Alpha
PYXIS ONCOLOGY, INC. : WELLS FARGO RAISES TARGET PRICE TO $19 FROM $12 - webull.com
Wells Fargo raises Pyxis Oncology stock price target on MICVO data By Investing.com - Investing.com South Africa
Wedbush raises Pyxis Oncology stock price target on trial data By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright By Investing.com - Investing.com Australia
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know - webull.com
Pyxis Oncology (NASDAQ: PYXS) to Launch Phase 3 Trial for MICVO in Mid-2027 Following Promising Phase 1 Results - Kalkine Media
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Nigeria
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $6 to $19 - Moomoo
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Australia
Wedbush raises Pyxis Oncology stock price target on trial data - Investing.com India
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2026-09-10 - Seeking Alpha
Pyxis Oncology Slides 7% as Analysts Flag Toxicity Concerns for Lead Cancer Drug - finance.biggo.com
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug - Benzinga
Wedbush Lifts Price Target on Pyxis Oncology to $8 From $6, Keeps Outperform Rating - marketscreener.com
Pyxis Oncology shares fall 7% despite updated MICVO trial results - Yahoo Finance
PYXS: MICVO showed strong efficacy and manageable safety in advanced head and neck cancer patients - TradingView
Pyxis Oncology stock falls 7% despite positive trial data By Investing.com - Investing.com Canada
Pyxis slides after new early-stage trial data for lead asset in head and neck cancer - TradingView
Pyxis Oncology Reports 36% Response Rate in Phase 1 MICVO Study - marketscreener.com
Pyxis Oncology Reports Promising MICVO Phase 1 Results - TipRanks
Pyxis Oncology reports 36% cORR, 6.2‑month mPFS and 79% 12‑month OS probability for MICVO in 2L+ HNSCC - TradingView
Head and neck cancer drug from Pyxis Oncology (PYXS) shows tumor responses ahead of 500-patient trial - stocktitan.net
A cancer treatment showed disease control in 94% of trial patients. Pyxis plans a roughly 500-patient trial. - stocktitan.net
PYXS: MICVO achieved rapid, deep responses and strong disease control in advanced head and neck cancer - TradingView
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Pyxis Oncology Shares Gain 9.25% After HoursPyxis Oncology (NASDAQ:PYXS) - Benzinga
Pyxis Oncology to present clinical data on cancer therapy By Investing.com - Investing.com South Africa
Pyxis Oncology to present clinical data on cancer therapy - investing.com
Updated cancer-drug data will be presented Sept. 9. A Memorial Sloan Kettering expert will join Pyxis Oncology. - Stock Titan
Pyxis Oncology Names Thomas Civik CEO and Chairman Ahead of MICVO Milestones - citybiz
Pyxis Oncology Appoints Thomas Civik as CEO and Chairman of the Board - Oncodaily
Pyxis Oncology Names Thomas Civik CEO, Board Chairman - marketscreener.com
Pyxis Oncology names Thomas Civik as permanent CEO and chairman By Investing.com - Investing.com Nigeria
Pyxis Oncology, Inc. Announces Board Changes - marketscreener.com
Pyxis Oncology, Inc. Announces Appointment of Thomas Civik to Chief Executive Officer, Effective September 4, 2026 - marketscreener.com
Pyxis Oncology Elevates Thomas Civik to Permanent CEO - TipRanks
Pyxis Oncology names Thomas Civik as permanent CEO and chairman - Investing.com India
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board - manilatimes.net
Pyxis Oncology (PYXS) CEO receives 2.5M options at $3.89 - Stock Titan
Pyxis Oncology Inc (PYXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):